Brief: SELLAS Announces First Patient Dosed In Phase 2A Clinical Trial Of GFH009 In Acute Myeloid Leukemia
22/06/2023 13:54
June 22 (Reuters) - SELLAS Life Sciences Group Inc
SLS.O :
* SELLAS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A CLINICAL
TRIAL
OF GFH009 IN ACUTE MYELOID LEUKEMIA
* SELLAS LIFE SCIENCES GROUP INC- TOPLINE DATA IS EXPECTED
DURING
Q4 OF THIS YEAR FOR GFH009
Source text for Eikon: ID:nGNX4SJ2Tp
Further company coverage: SLS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses